Bar Ilan University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ramat Gan Israel (1955)

Organization Overview

First Clinical Trial
2005
NCT00466401
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

1Department of Obstetrics & Gynecology, Galilee Medical Center, 2Faculty of Medicine in the Galilee, Bar Ilan University, Nahariya, Israel | Bar Ilan University | Bar-Ilan University, Israel | Department of Psychology, and the Gonda Brain Research center, Bar Ilan University | Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel | Feramda | Head of Fertility unit, Poriya' Bar Ilan University | Internal Medicine Department A, Ziv Medical Center | Poriya' Bar Ilan University | Prof. Ilanit gordon | Ziv Hospital | Ziv MC | Ziv Medical Center | Ziv medical center safed, israel | ZIV MEDICAL CENTER, SAFED ISRAEL | Ziv Medical Center, Zefat, Israel | Ziv Medical Centre, Safed, Israel / Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 1)

Fatty Liver (Phase 2)

Fetal Membranes, Premature Rupture (Phase 4)

Hypercholesterolemia (Phase 4)

Infertility (Phase 2)

Infertility, Female (Phase 2)

Iron Overload (Phase 2)

Liver Diseases (Phase 2)

Macular Degeneration (Phase 2)

Metabolic Syndrome (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Preleukemia (Phase 2)

Premature Birth (Phase 4)

Rupture (Phase 4)

Schizophrenia (Phase 3)

Sclerosis (Phase 2)

Substance-Related Disorders (Phase 1)

Syndrome (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 37